Species‐related exposure of phase II metabolite gemfibrozil 1‐O‐β‐glucuronide between human and mice: A net induction of mouse P450 activity was revealed. (20th November 2017)
- Record Type:
- Journal Article
- Title:
- Species‐related exposure of phase II metabolite gemfibrozil 1‐O‐β‐glucuronide between human and mice: A net induction of mouse P450 activity was revealed. (20th November 2017)
- Main Title:
- Species‐related exposure of phase II metabolite gemfibrozil 1‐O‐β‐glucuronide between human and mice: A net induction of mouse P450 activity was revealed
- Authors:
- Luo, Min
Dai, Manyun
Lin, Hante
Xie, Minzhu
Lin, Jiao
Liu, Aiming
Yang, Julin - Abstract:
- Abstract: Gemfibrozil is a fibrate drug used widely for dyslipidemia associated with atherosclerosis. Clinically, both gemfibrozil and its phase II metabolite gemfibrozil 1‐O‐β‐glucuronide (gem‐glu) are involved in drug–drug interaction (DDI). But the DDI risk caused by gem‐glu between human and mice has not been compared. In this study, six volunteers were recruited and took a therapeutic dose of gemfibrozil for 3 days for examination of the gemfibrozil and gem‐glu level in human. Male mice were fed a gemfibrozil diet (0.75%) for 7 days, following which a cocktail‐based inhibitory DDI experiment was performed. Plasma samples and liver tissues from mice were collected for determination of gemfibrozil, gem‐glu concentration and cytochrome p450 enzyme (P450) induction analysis. In human, the molar ratio of gem‐glu/gemfibrozil was 15% and 10% at the trough concentration and the concentration at 1.5 h after the 6th dose. In contrast, this molar ratio at steady state in mice was 91%, demonstrating a 6‐ to 9‐fold difference compared with that in human. Interestingly, a net induction of P450 activity and in vivo inductive DDI potential in mice was revealed. The P450 activity was not inhibited although the gem‐glu concentration was high. These data suggested species difference of relative gem‐glu exposure between human and mice, as well as a net inductive DDI potential of gemfibrozil in mouse model.
- Is Part Of:
- Biopharmaceutics & drug disposition. Volume 38:Number 9(2017:Dec.)
- Journal:
- Biopharmaceutics & drug disposition
- Issue:
- Volume 38:Number 9(2017:Dec.)
- Issue Display:
- Volume 38, Issue 9 (2017)
- Year:
- 2017
- Volume:
- 38
- Issue:
- 9
- Issue Sort Value:
- 2017-0038-0009-0000
- Page Start:
- 535
- Page End:
- 542
- Publication Date:
- 2017-11-20
- Subjects:
- drug–drug interactions -- gemfibrozil -- glucuronidation -- species difference
Biopharmaceutics -- Periodicals
Drugs -- Metabolism -- Periodicals
Pharmacology -- Periodicals
Biopharmaceutics -- Periodicals
Pharmaceutical Preparations -- metabolism -- Periodicals
615.19 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/bdd.2105 ↗
- Languages:
- English
- ISSNs:
- 0142-2782
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.355000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 5423.xml